 Connection
David Simpson to Antibodies, Monoclonal
This is a "connection" page, showing publications David Simpson has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.179 |
|
|
|
-
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Foss? A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug; 15(9):966-74.
Score: 0.075
-
Clifford DB, De Luca A, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010 Apr; 9(4):438-46.
Score: 0.056
-
Berkahn L, Simpson D, Raptis A, Klingemann HG. In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia. J Hematother Stem Cell Res. 2002 Apr; 11(2):315-20.
Score: 0.032
-
Andersson J, Simpson DM, Qi M, Wang Y, Elion EA. Differential input by Ste5 scaffold and Msg5 phosphatase route a MAPK cascade to multiple outcomes. EMBO J. 2004 Jul 07; 23(13):2564-76.
Score: 0.009
-
Heale JP, Pollard AJ, Stokes RW, Simpson D, Tsang A, Massing B, Speert DP. Two distinct receptors mediate nonopsonic phagocytosis of different strains of Pseudomonas aeruginosa. J Infect Dis. 2001 Apr 15; 183(8):1214-20.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|